BRIEF published on 11/26/2025 at 00:51, 5 months 6 days ago CureVac Announces Results of Extraordinary General Meeting BioNTech Extraordinary General Meeting CureVac Shareholders Approval Legal Merger
PRESS RELEASE published on 11/26/2025 at 00:46, 5 months 6 days ago CureVac Announces Voting Results of Extraordinary General Meeting CureVac announces approval of BioNTech's exchange offer for outstanding shares at Extraordinary General Meeting with over 99.16% approval rate BioNTech MRNA Technology Exchange Offer CureVac EGM Voting Results
BRIEF published on 11/24/2025 at 13:15, 5 months 7 days ago CureVac Reports Q3 and Nine-Month Financial Results for 2025 Financial Performance MRNA Technology CureVac Q3 2025 Results BioNTech Merger
PRESS RELEASE published on 11/24/2025 at 13:10, 5 months 7 days ago CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates CureVac announces financial results for Q3 and first nine months of 2025, BioNTech transaction progresses, EMA clearance received for cancer therapy CVHNLC sqNSCLC Financial Results Cancer Therapy CureVac BioNTech Transaction EMA Clearance
BRIEF published on 08/15/2025 at 13:32, 8 months 17 days ago CureVac Reports Q2 and H1 2025 Financial Results; Announces Key Developments Financial Results MRNA Technology CureVac Patent Resolution BioNTech Acquisition
PRESS RELEASE published on 08/15/2025 at 13:27, 8 months 17 days ago CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates CureVac announces Q2 2025 financial results, business updates & agreement with BioNTech for transformative mRNA treatments. Strong cash position Financial Results BioNTech CureVac MRNA Q2 2025
BRIEF published on 08/08/2025 at 02:20, 8 months 25 days ago CureVac Settles Patent Dispute with Pfizer/BioNTech MRNA Technology CureVac Pfizer/BioNTech Patent Resolution Vaccine Royalties
PRESS RELEASE published on 08/08/2025 at 02:15, 8 months 25 days ago CureVac Announces Resolution of Patent Litigation with Pfizer/BioNTech CureVac resolves patent litigation with Pfizer/BioNTech related to mRNA-based COVID-19 vaccines, receiving $790 million and non-exclusive license agreements BioNTech MRNA Technology CureVac Patent Litigation Pfizer
BRIEF published on 06/24/2025 at 22:14, 10 months 7 days ago CureVac Reports Outcomes of Annual General Meeting MRNA Technology Annual Meeting Board Appointments Auditors CureVac
PRESS RELEASE published on 06/24/2025 at 22:09, 10 months 7 days ago CureVac Announces Voting Results of General Meeting CureVac announces voting results of Annual General Meeting, including new Management Board and Supervisory Board appointments. KPMG reappointed as external auditors Annual General Meeting Appointments Voting Results KPMG CureVac
Published on 05/02/2026 at 01:30, 7 hours 39 minutes ago Uraniumx Reports Strong Financial Position Ahead of Spring Drill Program
Published on 05/02/2026 at 00:50, 8 hours 19 minutes ago CoTec Announces Annual Stock Option, Restricted Share Unit And Deferred Share Unit Grants
Published on 05/02/2026 at 00:00, 9 hours 9 minutes ago Redwood AI Announces Enhanced AI Models, Increasing Evaluated Chemical Reactions Following Preliminary Results from UBC Collaboration
Published on 05/02/2026 at 00:00, 9 hours 9 minutes ago Onco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram Non-GMP Synthesis to Support IND-Enabling Studies
Published on 05/01/2026 at 22:30, 10 hours 39 minutes ago Nextech3D.ai Appoints New Independent Auditor
Published on 05/01/2026 at 19:23, 13 hours 45 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 05/01/2026 at 17:45, 15 hours 23 minutes ago Burkhalter Group acquires Progressio Holding GmbH and anplaq ag, Tamins (GR)
Published on 05/01/2026 at 17:21, 15 hours 47 minutes ago Fuller, Smith & Turner PLC: Total Voting Rights and Treasury Shares
Published on 04/30/2026 at 20:00, 1 day 13 hours ago AMA Corp PLC : FY 2025 Earnings & Q1 2026 Revenue
Published on 04/30/2026 at 19:16, 1 day 13 hours ago AXA announces the results of its Shareholders' Meeting
Published on 04/30/2026 at 19:00, 1 day 14 hours ago Capital increase through exercise of subscription rights
Published on 04/30/2026 at 18:10, 1 day 14 hours ago Minutes of the Combined General Meeting held on April 30, 2026
